Search Results

You are looking at 171 - 180 of 383 items for :

  • "Neutropenia" x
  • Refine by Access: All x
Clear All
Full access

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2015

Andrew D. Zelenetz, Leo I. Gordon, William G. Wierda, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, John C. Byrd, Myron S. Czuczman, Luis E. Fayad, Richard I. Fisher, Martha J. Glenn, Thomas M. Habermann, Nancy Lee Harris, Richard T. Hoppe, Steven M. Horwitz, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Ayman A. Saad, Lubomir Sokol, Lode J. Swinnen, Christina Tsien, Julie M. Vose, Lynn Wilson, Joachim Yahalom, Nadeem Zafar, Mary Dwyer, and Hema Sundar

<.001) compared with rituximab plus chlorambucil. 81 The most frequent grade 3 or higher toxicities with obinutuzumab-chlorambucil included neutropenia (35%), infusion-related reactions (21%), thrombocytopenia (11%), and infections (11%). 81 The most

Full access

Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

Jerald P. Radich, Michael Deininger, Camille N. Abboud, Jessica K. Altman, Ellin Berman, Ravi Bhatia, Bhavana Bhatnagar, Peter Curtin, Daniel J. DeAngelo, Jason Gotlib, Gabriela Hobbs, Madan Jagasia, Hagop M. Kantarjian, Lori Maness, Leland Metheny, Joseph O. Moore, Arnel Pallera, Philip Pancari, Mrinal Patnaik, Enkhtsetseg Purev, Michal G. Rose, Neil P. Shah, B. Douglas Smith, David S. Snyder, Kendra L. Sweet, Moshe Talpaz, James Thompson, David T. Yang, Kristina M. Gregory, and Hema Sundar

reversible on discontinuation or dose reduction. 50 , 51 Dasatinib: In the DASISION study, the incidences of grade 3/4 hematologic toxicities (anemia, neutropenia, and thrombocytopenia) were higher for dasatinib than imatinib. Nonhematologic adverse events

Full access

Senior Adult Oncology

Arti Hurria, Ilene S. Browner, Harvey Jay Cohen, Crystal S. Denlinger, Mollie deShazo, Martine Extermann, Apar Kishor P. Ganti, Jimmie C. Holland, Holly M. Holmes, Mohana B. Karlekar, Nancy L. Keating, June McKoy, Bruno C. Medeiros, Ewa Mrozek, Tracey O’Connor, Stephen H. Petersdorf, Hope S. Rugo, Rebecca A. Silliman, William P. Tew, Louise C. Walter, Alva B. Weir III, and Tanya Wildes

, comorbidities, anthracycline-based regimens, a 28-day schedule, and febrile neutropenia as independent predictors of reduced dose-intensity among patients with early-stage breast cancer undergoing adjuvant chemotherapy. 167 In another retrospective analysis of

Full access

NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019

Featured Updates to the NCCN Guidelines

Andrew D. Zelenetz, Leo I. Gordon, Jeremy S. Abramson, Ranjana H. Advani, Nancy L. Bartlett, Paolo F. Caimi, Julie E. Chang, Julio C. Chavez, Beth Christian, Luis E. Fayad, Martha J. Glenn, Thomas M. Habermann, Nancy Lee Harris, Francisco Hernandez-Ilizaliturri, Mark S. Kaminski, Christopher R. Kelsey, Nadia Khan, Susan Krivacic, Ann S. LaCasce, Amitkumar Mehta, Auayporn Nademanee, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Kenneth B. Roberts, Stephen D. Smith, Erin D. Snyder, Lode J. Swinnen, Julie M. Vose, Mary A. Dwyer, and Hema Sundar

toxicities included neutropenia (27%), elevated alanine aminotransferase level (13%), diarrhea (13%), and pneumonia (7%), and thrombocytopenia (6%). In a post hoc analysis, median PFS was 8 months for patients with POD within 12 months compared with 14 months

Full access

Abstracts From the NCCN 2024 Annual Conference

and 1 EGC pts; DL1 TALA 0.5 mg: 4 pts, DL2 TALA 0.75 mg: 5 pts, DL3 TALA 1 mg: 5 pts). We are currently enrolling patients in DL3. There are no major toxicity signals to this date. There was one dose-limiting toxicity (DLT, grade 4 neutropenia) in DL1

Full access

Part 2: Abstracts From the NCCN 18th Annual Conference: Advancing the Standard of Cancer Care™

enrolled at dose level 1 (100 mg, qdx3, weekly), and 2 developed dose-limiting toxicities (DLTs). These DLTs included deep venous thrombosis/pulmonary embolism and grade IV febrile neutropenia in patient 1, and grade III febrile neutropenia and Clostridium

Full access

Small Cell Lung Cancer

Gregory P. Kalemkerian, Wallace Akerley, Paul Bogner, Hossein Borghaei, Laura QM Chow, Robert J. Downey, Leena Gandhi, Apar Kishor P. Ganti, Ramaswamy Govindan, John C. Grecula, James Hayman, Rebecca Suk Heist, Leora Horn, Thierry Jahan, Marianna Koczywas, Billy W. Loo Jr, Robert E. Merritt, Cesar A. Moran, Harvey B. Niell, Janis O’Malley, Jyoti D. Patel, Neal Ready, Charles M. Rudin, Charles C. Williams Jr, Kristina Gregory, and Miranda Hughes

biopsies may be indicated in select patients with nucleated red blood cells on peripheral blood smear, neutropenia, or thrombocytopenia and no other evidence of metastatic disease. Bone marrow involvement as the only site of extensive-stage disease occurs

Full access

Adherence to Hematologic Hold Parameters in Carboplatin and Dose-Dense Paclitaxel Chemotherapy for Ovarian Malignancies: A Survey of NCCN Member Institutions

Marina Stasenko, R. Kevin Reynolds, Carolyn Johnston, Melissa Brackman, Karen McLean, and Shitanshu Uppal

set at 50 × 10 9 /L ( Table 1 ). The frequency of grade 3 and 4 thrombocytopenia and neutropenia were similar in the dose-dense and conventional chemotherapy groups in the studies and, because of hold parameter modifications, the JGOG trial noted that

Full access

Updates to the Management of Chronic Lymphocytic Leukemia

William G. Wierda

the German CLL Study Group comparing fludarabine and cyclophosphamide (FC) to FC plus rituximab (FCR) for previously untreated patients with chronic lymphocytic leukemia: results on survival, progression-free survival, delayed neutropenias and

Full access

Management of Dermatologic Toxicities

Mario E. Lacouture

70%, versus reactive treatment, and also reduced pruritus, secondary infections, and paronychia as well as non-dermatologic toxicities grade 3 or greater (diarrhea, neutropenia, etc). 4 “Importantly, prophylaxis does not negate the beneficial anti